admin

Mefenamic Acid: Fenamate NSAID, Dysmenorrhea, Short-Course Dosing and Safety

Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information. Overview and chemical classification Mefenamic acid is an anthranilic acid-derived NSAID of the fenamate family, correctly named 2-[(2,3-dimethylphenyl)amino]benzoic acid. It reversibly inhibits cyclooxygenase COX-1 and COX-2, suppressing prostaglandin synthesis. The original monograph’s chemical name was inaccurate,…

Read Full News

Ketorolac: Pyrrolizine NSAID, Five-Day Limit, Renal Injury and Bleeding Warnings

Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information. Overview and classification Ketorolac is a potent nonselective COX-1/COX-2-inhibiting NSAID derived from a pyrrolizine carboxylic acid structure, not an oxicam. It treats selected moderately severe acute pain requiring analgesia at the opioid level, often after surgery….

Read Full News

Naproxen: Propionic-Acid NSAID, Analgesia, Inflammation and Risk Reduction

Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information. Overview and pharmacology Naproxen is a nonselective COX-inhibiting arylpropionic acid NSAID available in prescription and selected OTC formulations. It reduces pain, inflammation and fever, including in osteoarthritis, inflammatory arthritis, dysmenorrhea, tendinitis and acute gout. It treats…

Read Full News

Indomethacin: Indoleacetic-Acid NSAID, Acute Gout and Adverse-Effect Precautions

Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information. Overview and classification Indomethacin (indometacin) is a potent nonselective NSAID in the indoleacetic acid derivative family, not the propionic-acid family. It inhibits COX-mediated prostaglandin synthesis and has recognized anti-inflammatory and analgesic effects. Its relatively high CNS,…

Read Full News

Rocuronium: Aminosteroid Neuromuscular Blocker, Quantitative Monitoring and Sugammadex

Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information. Overview and corrected chemical class Rocuronium bromide is a synthetic aminosteroid nondepolarizing neuromuscular blocker, not a benzylisoquinolinium agent. It competitively blocks muscle-type nicotinic acetylcholine receptors at the motor endplate, preventing acetylcholine-triggered skeletal muscle depolarization. Its rapid…

Read Full News

Pancuronium: Aminosteroid Neuromuscular Blockade, Prolonged Paralysis and Monitoring

Evidence-informed pharmacology monograph. Updated 10 November 2026. For education; drug selection and administration require current local labeling, relevant protocols and patient-specific evaluation. Overview and pharmacologic classification Pancuronium bromide is a long-acting aminosteroid, nondepolarizing neuromuscular blocking agent (NMBA). It competitively blocks muscle-type nicotinic acetylcholine receptors at the motor end plate, preventing depolarization and skeletal muscle contraction….

Read Full News

Tamsulosin: Alpha-1A Blockade, BPH Symptoms, Orthostatic Risk and Cataract Precautions

Evidence-informed pharmacology monograph. Updated 10 November 2026. For education; drug selection and administration require current local labeling, relevant protocols and patient-specific evaluation. Overview and receptor pharmacology Tamsulosin is a sulfonamide-containing, relatively uroselective alpha-1 adrenergic receptor antagonist with affinity for alpha-1A and alpha-1D receptors. It reduces alpha-1-mediated smooth-muscle tone in the prostate and bladder neck, improving…

Read Full News

Carvedilol: Beta/Alpha-1 Blockade, HFrEF Survival Benefit and Safety

Evidence-informed pharmacology monograph. Updated 10 November 2026. For education; drug selection and administration require current local labeling, relevant protocols and patient-specific evaluation. Overview and receptor mechanisms Carvedilol is a nonselective beta-1/beta-2 adrenergic receptor blocker with additional alpha-1 antagonism. Its beta blockade lowers heart rate, myocardial oxygen demand and renin release, while alpha-1 blockade reduces vascular…

Read Full News

Labetalol: Mixed Alpha/Beta Blockade, Severe Hypertension and Obstetric Safety

Evidence-informed pharmacology monograph. Updated 10 November 2026. For education; drug selection and administration require current local labeling, relevant protocols and patient-specific evaluation. Overview and mechanism Labetalol is a mixed adrenergic antagonist with nonselective beta-1/beta-2 and alpha-1 blocking activity. Beta blockade slows rate, AV conduction and renin secretion, while alpha-1 blockade reduces peripheral resistance. Compared with…

Read Full News

Labetalol Monograph: α1/β Blockade, Severe Hypertension, Obstetric Use and Safety

Evidence-informed pharmacology monograph, reviewed 10 November 2026. Educational content; drug administration and prescribing require current local labels, institutional protocols and individualized clinical assessment. Overview and learning objectives Labetalol is a mixed adrenergic antagonist that blocks vascular α1 receptors and cardiac/bronchial β1 and β2 receptors. It is used orally for selected chronic hypertension regimens and intravenously…

Read Full News